Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inhibikase Therapeutics, Inc.

1.89
-0.0100-0.53%
Post-market: 1.890.00000.00%16:05 EDT
Volume:62.38K
Turnover:117.01K
Market Cap:140.51M
PE:-1.63
High:1.90
Open:1.85
Low:1.79
Close:1.90
Loading ...

Company Profile

Company Name:
Inhibikase Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
16
Office Location:
3350 Riverwood Parkway SE,Suite 1900,Atlanta,Georgia,United States
Zip Code:
30339
Fax:
- -
Introduction:
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Directors

Name
Position
Milton H. Werner
President, Chief Executive Officer and Director
Dennis Berman
Director
Elizabeth O'Farrell
Director
Paul Grint
Director
Roy Freeman
Director

Shareholders

Name
Position
Milton H. Werner
President, Chief Executive Officer and Director
Joseph Frattaroli
Chief Financial Officer